A recent research has shed light on an experimental Alzheimer's drug, by Eli Lilly & Company, which might be able to deal with the mild cases. However, they would have to go for another trial in order to confirm that the drug, solanezumab, is effective enough.

The makers have apparently observed that the drug is capable enough to slow memory decline, while they conducted the research on over 1000 patients earlier. After the research, they found that some 34% mild Alzheimer's patients faced reduced mental decline for a period of 18 months.

Thus before approaching U. S. regulatory approval, the makers are going for another trial to confirm their results. There are fair chances of the research to be over by the second half of 2015, and hopefully, the drug would be able to make its way in the market in 2017.

"We are committed to working with the F. D. A. and other regulatory authorities to bring solanezumab to the millions of patients and caregivers suffering from this devastating disease who urgently need this potential treatment", said David Ricks, a senior vice president at Lilly and president of Lilly Bio-Medicines.

Though the shares of the company saw a rise of 16% after the initial results in August, they faced a drop of $1.60, or 3.2%, to $49, after the announcement of the second trial.